Notwithstanding encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from pharmacy benefit managers. The insurers https://gregoryarpk608739.ampedpages.com/company-s-drug-faces-is-encountering-pbm-hurdles-the-look-of-reimbursement-disputes-69066032